Massachusetts scientific instrument maker Harvard Bioscience named Jeffrey Duchemin its new CEO, who took over the company in the midst of the spinout of its regenerative therapies unit.
Duchemin, a veteran of Becton Dickinson & Co. (NYSE:BDX) and former global business director for Corning Life Sciences, took the office from interim CEO and long-time company president David Green, who will step down from his role as president when the spinout is completed, according to a statement.
"As a co-founder of Harvard Bioscience, and having been its President for over 17 years, I am very pleased to introduce Jeff as the Company’s new CEO," Green said in prepared remarks. "I am one of the company’s largest shareholders and I have great confidence that Jeff can lead Harvard Bioscience to the next level of growth and value creation for all our shareholders."
Duchemin enters the picture just as Harvard Bio is filing documents to solidify the spinout of its Harvard Apparatus Regenerative Technology subsidiary, a move announced in December 2012. The companies last week filed the initial Form 10 Registration Statement related to the separation, which is contingent on factors including a $15 capital contribution to HART and executive of a Separation & Distribution Agreement, the company announced.